Jafral
JAFRAL is an independent Contract Manufacturing Organization (CMO) & Contract Research Organization (CRO) specializing in phage, pDNA, and protein production. It is the world's only CMO focused primarily on the production of non-GMP and GMP bacteriophages. JAFRAL provides comprehensive services including development, manufacturing, analytics, and regulatory support for biopharmaceutical products, especially in the field of phage therapy, gene therapy, and biologics.
Industries
Nr. of Employees
small (1-50)
Jafral
Ljubljana, Ljubljana Urban Commune, Slovenia, Europe
Products
Bacteriophage preparations
Manufacture and analytical support for bacteriophage preparations intended for therapeutics, veterinary use, food safety, diagnostics, agriculture and environmental applications.
Plasmid DNA (pDNA) products
Manufacture of plasmid DNA including minicircular formats and size-specific production for small (2–15 kb) and large (15–100 kb) plasmids.
Recombinant proteins
Production and analytical services for recombinant proteins intended for therapeutic, diagnostic and research applications.
Bacteriophage preparations
Manufacture and analytical support for bacteriophage preparations intended for therapeutics, veterinary use, food safety, diagnostics, agriculture and environmental applications.
Plasmid DNA (pDNA) products
Manufacture of plasmid DNA including minicircular formats and size-specific production for small (2–15 kb) and large (15–100 kb) plasmids.
Recombinant proteins
Production and analytical services for recombinant proteins intended for therapeutic, diagnostic and research applications.
Services
Process design and optimization to enable scale-up and transfer to GMP manufacturing for biologics.
Creation, characterization and release testing of master and working banks for cells and viruses for use in production.
Contract manufacturing of active drug substances and finished drug products (sterile and non-sterile), including formulation options and downstream processing.
Aseptic filling and finishing services for clinical trial material and other sterile products under GMP or non‑GMP conditions.
Development and validation of analytical methods and provision of contract analytical testing to support product characterization and regulatory requirements.
Design and execution of stability studies to determine product shelf-life and storage conditions for regulatory filings.
Process design and optimization to enable scale-up and transfer to GMP manufacturing for biologics.
Creation, characterization and release testing of master and working banks for cells and viruses for use in production.
Contract manufacturing of active drug substances and finished drug products (sterile and non-sterile), including formulation options and downstream processing.
Aseptic filling and finishing services for clinical trial material and other sterile products under GMP or non‑GMP conditions.
Development and validation of analytical methods and provision of contract analytical testing to support product characterization and regulatory requirements.
Design and execution of stability studies to determine product shelf-life and storage conditions for regulatory filings.
Expertise Areas
- Phage manufacturing and analytics
- Plasmid DNA production and scale-up
- Recombinant protein production
- CMC and clinical trial material support
Key Technologies
- GMP manufacturing with classified cleanrooms (Grade A-D)
- Sterile aseptic fill–finish
- Lyophilization and spray drying for biologics
- Plasmid DNA production and purification
News & Updates
JAFRAL will participate in the Phage Therapy conference in Germany, 2025.
JAFRAL helped SNIPR BIOME produce clinical trial material for their first-in-human CRISPR-based therapeutic.
JAFRAL is a partner of the 4th Bacteriophage Therapy Summit, supporting the phage community.
JAFRAL announced the acquisition of a fully certified GMP production facility with manufacturing suits and QC labs, enabling production of clinical trial material.
JAFRAL was invited to give a talk on production of phage-based products at the FDA-NIH Workshop.
JAFRAL sponsored the Bacteriophage Therapy Summit in Boston, USA, and participated with a representative.
JAFRAL will participate in the Phage Therapy conference in Germany, 2025.
JAFRAL helped SNIPR BIOME produce clinical trial material for their first-in-human CRISPR-based therapeutic.
JAFRAL is a partner of the 4th Bacteriophage Therapy Summit, supporting the phage community.
JAFRAL announced the acquisition of a fully certified GMP production facility with manufacturing suits and QC labs, enabling production of clinical trial material.
JAFRAL was invited to give a talk on production of phage-based products at the FDA-NIH Workshop.
JAFRAL sponsored the Bacteriophage Therapy Summit in Boston, USA, and participated with a representative.